Bruce L. A. Carter - 12 Aug 2022 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role
Director
Signature
/s/Reena Desai, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
12 Aug 2022
Net transactions value
-$584,899
Form type
4
Filing time
16 Aug 2022, 16:15:53 UTC
Previous filing
22 Mar 2022
Next filing
24 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Options Exercise $270,000 +10,000 +166% $27.00 16,021 12 Aug 2022 Direct
transaction MRTX Common Stock Sale $434,287 -5,107 -32% $85.04 10,914 12 Aug 2022 Direct F1
transaction MRTX Common Stock Sale $420,612 -4,893 -45% $85.96 6,021 12 Aug 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRTX Non Qualified Stock Option (right to buy) Options Exercise $0 -10,000 -100% $0.000000* 0 12 Aug 2022 Common Stock 10,000 $27.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $84.55 to $85.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed in multiple trades at prices ranging from $85.60 to $86.555. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The shares subject to the Option vested and became exercisable in 12 equal monthly installments following the date of grant.